"Our research suggests that aspirin should not be prescribed to the general population at this stage," the Telegraph quoted Prof. Gerry Fowkes, of the Wolfson Unit for Prevention of Peripheral Vascular Disease in Edinburgh, as saying.
He added: "Aspirin probably leads to a minor reduction in future events but the problem is that has to be weighed against an increase in bleeding. Some of that bleeding can be quite serious and lead to death."
Prof. Peter Weissberg, Medical Director of the British Heart Foundation, which part-funded the study, said: "A lot of the worried well buy a small dose of aspirin over the counter not understanding that they are increasing their risk substantially of a major bleed."
He said that it is known that aspirin does reduce the risk of cardiovascular problems but this must be countered against the increased risk of internal bleeding.
In patients who have already had a heart attack the risk of a second is so much higher that the balance is in favour of taking aspirin.
However, for people who have not had a heart attack the risks do not normally outweigh the benefits.
In the study conducted in Scotland 29,000 men and women aged between 50 and 75 were screened to see if they had furred arteries in the legs, which means they are at high risk of developing heart disease but do not yet have symptoms.
More than 3,000 men were randomly assigned to receive a daily dose of aspirin or a dummy pill and were followed up for an average of eight years.
The researchers found no difference in the rate of heart attacks or stroke between the two groups and deaths from any cause were similar.
However, there were 34 major bleeds in people taking aspirin, or two per cent, compared with 20 or 1.2 per cent of those on the placebo.
He said the tablets were only taken 60 per cent of the time during the trial, which reflects real life experience in people who have not had a heart attack.
He said that in secondary prevention, where people have already had one attack and are trying to prevent a second one, compliance is usually better.
The study has been presented at the European Society of Cardiology Congress in Barcelona.
Source-ANI
SRM